Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Detalles Bibliográficos
Autores principales: Yi, Yali, Cai, Jing, Xu, Peng, Xiong, Le, Lu, Zhiqin, Zeng, Zhimin, Liu, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238048/
https://www.ncbi.nlm.nih.gov/pubmed/35761407
http://dx.doi.org/10.1186/s12967-022-03453-0
_version_ 1784736940743983104
author Yi, Yali
Cai, Jing
Xu, Peng
Xiong, Le
Lu, Zhiqin
Zeng, Zhimin
Liu, Anwen
author_facet Yi, Yali
Cai, Jing
Xu, Peng
Xiong, Le
Lu, Zhiqin
Zeng, Zhimin
Liu, Anwen
author_sort Yi, Yali
collection PubMed
description
format Online
Article
Text
id pubmed-9238048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92380482022-06-29 Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer Yi, Yali Cai, Jing Xu, Peng Xiong, Le Lu, Zhiqin Zeng, Zhimin Liu, Anwen J Transl Med Correction BioMed Central 2022-06-27 /pmc/articles/PMC9238048/ /pubmed/35761407 http://dx.doi.org/10.1186/s12967-022-03453-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correction
Yi, Yali
Cai, Jing
Xu, Peng
Xiong, Le
Lu, Zhiqin
Zeng, Zhimin
Liu, Anwen
Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title_full Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title_fullStr Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title_full_unstemmed Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title_short Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
title_sort correction: potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with egfr mutant non-small-cell lung cancer
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238048/
https://www.ncbi.nlm.nih.gov/pubmed/35761407
http://dx.doi.org/10.1186/s12967-022-03453-0
work_keys_str_mv AT yiyali correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT caijing correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT xupeng correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT xiongle correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT luzhiqin correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT zengzhimin correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer
AT liuanwen correctionpotentialbenefitofosimertinibplusbevacizumabinleptomeningealmetastasiswithegfrmutantnonsmallcelllungcancer

Ejemplares similares